Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and dopamine communication. While GCGR agonists are widely employed for addressing type 2 diabetes, their unexpected consequences on reward circuits, specifically mediated by DA sy